We have developed a new method for producing red blood cells that is efficient and scalable. By introducing genes into RBC progenitor cells we can create cell lines that can be amplified, modified and differentiated into RBCs with high efficiencies.
We have filed a provisional patent with the USPTO: "Methods for Producing Erythroid Cell Lines and Red Blood Cells"
Our cell production platform is ideal to produce modified RBCs. By creating RBC progenitor cell lines from universal donor blood cells, we can establish a universal RBC production platform. By introducing genes into the progenitor cells we can modify, characterize, and expand those cells before differentiating them into modified RBCs.
The beauty of our technology is that we can bank our cell lines and produce large batches of well characterized homogeneous cells without the need for donors. We have conceptual designs for multiple drug products and hope to soon be testing pre-clinical candidates for applications in clinical cellular therapy. For more details or to discuss opportunities to collaborate please contact us.